Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt 14.32
NRCIA's Cash-to-Debt is ranked higher than
61% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.44 vs. NRCIA: 14.32 )
Ranked among companies with meaningful Cash-to-Debt only.
NRCIA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.05  Med: 2.03 Max: No Debt
Current: 14.32
Equity-to-Asset 0.71
NRCIA's Equity-to-Asset is ranked higher than
61% of the 208 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. NRCIA: 0.71 )
Ranked among companies with meaningful Equity-to-Asset only.
NRCIA' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.51  Med: 0.67 Max: 0.81
Current: 0.71
0.51
0.81
Debt-to-Equity 0.03
NRCIA's Debt-to-Equity is ranked higher than
89% of the 141 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.31 vs. NRCIA: 0.03 )
Ranked among companies with meaningful Debt-to-Equity only.
NRCIA' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01  Med: 0.16 Max: 0.36
Current: 0.03
0.01
0.36
Interest Coverage 288.41
NRCIA's Interest Coverage is ranked higher than
61% of the 152 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 59.16 vs. NRCIA: 288.41 )
Ranked among companies with meaningful Interest Coverage only.
NRCIA' s Interest Coverage Range Over the Past 10 Years
Min: 23.53  Med: 52.24 Max: 288.41
Current: 288.41
23.53
288.41
Piotroski F-Score: 8
Altman Z-Score: 17.68
Beneish M-Score: -2.45
WACC vs ROIC
2.68%
40.55%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 30.33
NRCIA's Operating Margin % is ranked higher than
96% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.05 vs. NRCIA: 30.33 )
Ranked among companies with meaningful Operating Margin % only.
NRCIA' s Operating Margin % Range Over the Past 10 Years
Min: 21.86  Med: 25.29 Max: 30.33
Current: 30.33
21.86
30.33
Net Margin % 19.92
NRCIA's Net Margin % is ranked higher than
94% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.21 vs. NRCIA: 19.92 )
Ranked among companies with meaningful Net Margin % only.
NRCIA' s Net Margin % Range Over the Past 10 Years
Min: 13.41  Med: 15.99 Max: 19.92
Current: 19.92
13.41
19.92
ROE % 27.35
NRCIA's ROE % is ranked higher than
91% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.23 vs. NRCIA: 27.35 )
Ranked among companies with meaningful ROE % only.
NRCIA' s ROE % Range Over the Past 10 Years
Min: 17.31  Med: 21.98 Max: 27.35
Current: 27.35
17.31
27.35
ROA % 18.72
NRCIA's ROA % is ranked higher than
94% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.45 vs. NRCIA: 18.72 )
Ranked among companies with meaningful ROA % only.
NRCIA' s ROA % Range Over the Past 10 Years
Min: 10.1  Med: 12.72 Max: 18.72
Current: 18.72
10.1
18.72
ROC (Joel Greenblatt) % 292.76
NRCIA's ROC (Joel Greenblatt) % is ranked higher than
97% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.76 vs. NRCIA: 292.76 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NRCIA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 94.26  Med: 154.01 Max: 292.76
Current: 292.76
94.26
292.76
3-Year Revenue Growth Rate 5.50
NRCIA's 3-Year Revenue Growth Rate is ranked higher than
51% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.50 vs. NRCIA: 5.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NRCIA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 10.3 Max: 19.8
Current: 5.5
0
19.8
3-Year EBITDA Growth Rate 7.50
NRCIA's 3-Year EBITDA Growth Rate is ranked higher than
54% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. NRCIA: 7.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NRCIA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 10.6 Max: 44.1
Current: 7.5
0
44.1
3-Year EPS without NRI Growth Rate 9.70
NRCIA's 3-Year EPS without NRI Growth Rate is ranked higher than
60% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.80 vs. NRCIA: 9.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NRCIA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 11.1 Max: 58.7
Current: 9.7
0
58.7
GuruFocus has detected 7 Warning Signs with National Research Corp $NRCIA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NRCIA's 30-Y Financials

Financials (Next Earnings Date: 2017-11-02 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

NRCIA Guru Trades in Q3 2016

Jim Simons 108,689 sh (+6.77%)
Chuck Royce 40,033 sh (unchged)
» More
Q4 2016

NRCIA Guru Trades in Q4 2016

Jim Simons 127,200 sh (+17.03%)
Chuck Royce 40,033 sh (unchged)
» More
Q1 2017

NRCIA Guru Trades in Q1 2017

Chuck Royce 124,885 sh (+211.96%)
Jim Simons 138,400 sh (+8.81%)
» More
Q2 2017

NRCIA Guru Trades in Q2 2017

Chuck Royce 240,417 sh (+92.51%)
Jim Simons 173,200 sh (+25.14%)
» More
» Details

Insider Trades

Latest Guru Trades with NRCIA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621399    SIC: 8099
Compare:NAS:ALOG, NAS:NEO, NAS:ABAX, NAS:BEAT, NAS:GHDX, NAS:NTRA, NAS:HSKA, NAS:MEDP, NAS:LNTH, NAS:PACB, NAS:QDEL, NAS:VREX, NAS:VIVO, NAS:RDNT, NAS:AXDX, NYSE:ENZ, NYSE:ARA, NYSE:NVTA, AMEX:SENS, NAS:FMI » details
Traded in other countries:NR1A.Germany,
Headquarter Location:USA
National Research Corp provides analytics and insights that improves measurement and improvement of the patient and employee experience. Its subscription-based solutions provide actionable information and analysis to healthcare organizations.

National Research Corp is a Wisconsin corporation, founded in 1981. The Company implements surveys and performs analysis that recognize a provider's strengths and problem areas, and then uses the data to design specific, measurable improvement strategies. The Company's portfolio of subscription-based solutions provide actionable information and analysis to healthcare organizations and payers across a range of mission-critical, constituent-related elements, including patient experience and satisfaction, community population health risks, workforce engagement, community perceptions, and physician engagement. The Company partners with clients across the continuum of healthcare services. The Company's clients range from acute care hospitals and post-acute providers, such as home health, long term care and hospice, to numerous payer organizations. The two segments, organized by geographic area, are National Research Corporation (United States) and National Research Corporation Canada, which each offer a portfolio of solutions to address specific market needs around growth, retention, engagement and thought leadership for healthcare organizations. The Company's primary competitors among such specialty firms include Press Ganey. The Company competes with traditional market research firms which are providers of survey-based, general market research and firms which provide services or products that complement healthcare performance assessments such as healthcare software or information systems.

Ratios

vs
industry
vs
history
PE Ratio 18.29
NRCIA's PE Ratio is ranked higher than
86% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.78 vs. NRCIA: 18.29 )
Ranked among companies with meaningful PE Ratio only.
NRCIA' s PE Ratio Range Over the Past 10 Years
Min: 2.19  Med: 3.89 Max: 20.25
Current: 18.29
2.19
20.25
PE Ratio without NRI 18.29
NRCIA's PE Ratio without NRI is ranked higher than
86% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 38.46 vs. NRCIA: 18.29 )
Ranked among companies with meaningful PE Ratio without NRI only.
NRCIA' s PE Ratio without NRI Range Over the Past 10 Years
Min: 2.19  Med: 3.89 Max: 20.25
Current: 18.29
2.19
20.25
Price-to-Owner-Earnings 19.02
NRCIA's Price-to-Owner-Earnings is ranked higher than
91% of the 68 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.54 vs. NRCIA: 19.02 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
NRCIA' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 1.42  Med: 3.36 Max: 21.01
Current: 19.02
1.42
21.01
PB Ratio 16.33
NRCIA's PB Ratio is ranked lower than
94% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.89 vs. NRCIA: 16.33 )
Ranked among companies with meaningful PB Ratio only.
NRCIA' s PB Ratio Range Over the Past 10 Years
Min: 0.42  Med: 0.76 Max: 18
Current: 16.33
0.42
18
PS Ratio 3.67
NRCIA's PS Ratio is ranked higher than
61% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.65 vs. NRCIA: 3.67 )
Ranked among companies with meaningful PS Ratio only.
NRCIA' s PS Ratio Range Over the Past 10 Years
Min: 0.32  Med: 0.59 Max: 4.03
Current: 3.67
0.32
4.03
Price-to-Free-Cash-Flow 18.76
NRCIA's Price-to-Free-Cash-Flow is ranked higher than
85% of the 78 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.07 vs. NRCIA: 18.76 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
NRCIA' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 1.44  Med: 3.23 Max: 20.74
Current: 18.76
1.44
20.74
Price-to-Operating-Cash-Flow 15.81
NRCIA's Price-to-Operating-Cash-Flow is ranked higher than
86% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.14 vs. NRCIA: 15.81 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
NRCIA' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 1.23  Med: 2.79 Max: 17.48
Current: 15.81
1.23
17.48
EV-to-EBIT 27.56
NRCIA's EV-to-EBIT is ranked higher than
63% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. NRCIA: 27.56 )
Ranked among companies with meaningful EV-to-EBIT only.
NRCIA' s EV-to-EBIT Range Over the Past 10 Years
Min: 1.5  Med: 2.9 Max: 30.57
Current: 27.56
1.5
30.57
EV-to-EBITDA 24.48
NRCIA's EV-to-EBITDA is ranked higher than
55% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.58 vs. NRCIA: 24.48 )
Ranked among companies with meaningful EV-to-EBITDA only.
NRCIA' s EV-to-EBITDA Range Over the Past 10 Years
Min: 1.2  Med: 2.3 Max: 27.14
Current: 24.48
1.2
27.14
EV-to-Revenue 8.45
NRCIA's EV-to-Revenue is ranked lower than
64% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.97 vs. NRCIA: 8.45 )
Ranked among companies with meaningful EV-to-Revenue only.
NRCIA' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.4  Med: 0.7 Max: 3.3
Current: 8.45
0.4
3.3
Shiller PE Ratio 19.12
NRCIA's Shiller PE Ratio is ranked higher than
90% of the 31 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 47.44 vs. NRCIA: 19.12 )
Ranked among companies with meaningful Shiller PE Ratio only.
NRCIA' s Shiller PE Ratio Range Over the Past 10 Years
Min: 3.49  Med: 6.72 Max: 21.11
Current: 19.12
3.49
21.11
Current Ratio 1.65
NRCIA's Current Ratio is ranked lower than
74% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.73 vs. NRCIA: 1.65 )
Ranked among companies with meaningful Current Ratio only.
NRCIA' s Current Ratio Range Over the Past 10 Years
Min: 0.49  Med: 1.54 Max: 5.41
Current: 1.65
0.49
5.41
Quick Ratio 1.65
NRCIA's Quick Ratio is ranked lower than
65% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. NRCIA: 1.65 )
Ranked among companies with meaningful Quick Ratio only.
NRCIA' s Quick Ratio Range Over the Past 10 Years
Min: 0.49  Med: 1.54 Max: 5.41
Current: 1.65
0.49
5.41
Days Sales Outstanding 42.02
NRCIA's Days Sales Outstanding is ranked higher than
75% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.84 vs. NRCIA: 42.02 )
Ranked among companies with meaningful Days Sales Outstanding only.
NRCIA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 29.97  Med: 45.13 Max: 57.87
Current: 42.02
29.97
57.87
Days Payable 6.75
NRCIA's Days Payable is ranked lower than
95% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 57.91 vs. NRCIA: 6.75 )
Ranked among companies with meaningful Days Payable only.
NRCIA' s Days Payable Range Over the Past 10 Years
Min: 3  Med: 8.15 Max: 184.63
Current: 6.75
3
184.63

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 1.01
NRCIA's Dividend Yield % is ranked higher than
95% of the 103 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.94 vs. NRCIA: 1.01 )
Ranked among companies with meaningful Dividend Yield % only.
NRCIA' s Dividend Yield % Range Over the Past 10 Years
Min: 0.92  Med: 12.68 Max: 23.19
Current: 1.01
0.92
23.19
Dividend Payout Ratio 0.12
NRCIA's Dividend Payout Ratio is ranked higher than
86% of the 66 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.34 vs. NRCIA: 0.12 )
Ranked among companies with meaningful Dividend Payout Ratio only.
NRCIA' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.12  Med: 0.51 Max: 0.7
Current: 0.12
0.12
0.7
3-Year Dividend Growth Rate 48.70
NRCIA's 3-Year Dividend Growth Rate is ranked higher than
82% of the 34 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. NRCIA: 48.70 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
NRCIA' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 48.7
Current: 48.7
0
48.7
Forward Dividend Yield % 1.07
NRCIA's Forward Dividend Yield % is ranked higher than
91% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.11 vs. NRCIA: 1.07 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.93
NRCIA's 5-Year Yield-on-Cost % is ranked higher than
83% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.46 vs. NRCIA: 0.93 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
NRCIA' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.84  Med: 11.52 Max: 21.07
Current: 0.93
0.84
21.07
3-Year Average Share Buyback Ratio -0.30
NRCIA's 3-Year Average Share Buyback Ratio is ranked higher than
80% of the 146 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.50 vs. NRCIA: -0.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NRCIA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -93.8  Med: 0 Max: 0
Current: -0.3
-93.8
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 101.22
NRCIA's Price-to-Net-Current-Asset-Value is ranked lower than
96% of the 140 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.24 vs. NRCIA: 101.22 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
NRCIA' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.33  Med: 1.76 Max: 716.4
Current: 101.22
0.33
716.4
Price-to-Tangible-Book 52.75
NRCIA's Price-to-Tangible-Book is ranked lower than
98% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.17 vs. NRCIA: 52.75 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NRCIA' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.21  Med: 0.77 Max: 2687.69
Current: 52.75
0.21
2687.69
Price-to-Intrinsic-Value-Projected-FCF 1.64
NRCIA's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
78% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.25 vs. NRCIA: 1.64 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
NRCIA' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.12  Med: 0.26 Max: 1.82
Current: 1.64
0.12
1.82
Price-to-Median-PS-Value 6.17
NRCIA's Price-to-Median-PS-Value is ranked lower than
98% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.04 vs. NRCIA: 6.17 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NRCIA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.25  Med: 0.89 Max: 6.82
Current: 6.17
0.25
6.82
Price-to-Graham-Number 6.56
NRCIA's Price-to-Graham-Number is ranked lower than
77% of the 74 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.54 vs. NRCIA: 6.56 )
Ranked among companies with meaningful Price-to-Graham-Number only.
NRCIA' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.12  Med: 0.47 Max: 32.96
Current: 6.56
0.12
32.96
Earnings Yield (Greenblatt) % 3.60
NRCIA's Earnings Yield (Greenblatt) % is ranked higher than
82% of the 230 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.04 vs. NRCIA: 3.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NRCIA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.26  Med: 34.1 Max: 68.2
Current: 3.6
3.26
68.2
Forward Rate of Return (Yacktman) % -2.41
NRCIA's Forward Rate of Return (Yacktman) % is ranked lower than
82% of the 65 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.57 vs. NRCIA: -2.41 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
NRCIA' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -3.1  Med: 38 Max: 65.1
Current: -2.41
-3.1
65.1

More Statistics

Revenue (TTM) (Mil) $114.11
EPS (TTM) $ 3.19
Beta1.66
Short Percentage of Float1.67%
52-Week Range $14.35 - 41.99
Shares Outstanding (Mil)24.48

Analyst Estimate

Dec17
Revenue (Mil $)
EPS ($) 0.93
EPS without NRI ($) 0.93
EPS Growth Rate
(Future 3Y To 5Y Estimate)
13.00%
Dividends per Share ($)
» More Articles for NRCIA

Headlines

Articles On GuruFocus.com
National Research Corporation Adopts Class B Reverse Stock Split to Eliminate Public Trading of Cl Sep 18 2017 
National Research Corporation Declares Quarterly Dividend Sep 01 2017 
Warden Retires From National Research Corporation Board of Directors Aug 30 2017 
NRC Health announces partnership to prevent physician burnout and improve the patient experience Aug 14 2017 
NRC Health publishes 10 millionth online patient rating Aug 07 2017 
National Research Corporation to Broadcast its 2017 Second Quarter Conference Call Live on the Inter Jul 18 2017 
Eleventh annual Excellence in Action awards recognize long-term care and senior living organizations Jun 22 2017 
Eleventh annual Excellence in Action awards recognize long-term care and senior living organizations Jun 22 2017 
National Research Corporation to Broadcast its 2017 First Quarter Conference Call Live on the Intern Apr 17 2017 
Backtesting Feature Identifies Top-Performing Strategies Aug 31 2016 

More From Other Websites
NRC Health launches metric to measure and grow healthcare consumer loyalty Sep 22 2017
National Research Corporation Adopts Class B Reverse Stock Split to Eliminate Public Trading of... Sep 18 2017
Warden Retires From National Research Corporation Board of Directors Aug 30 2017
NRC Health announces partnership to prevent physician burnout and improve the patient experience Aug 14 2017
National Research Corp. :NRCIA-US: Earnings Analysis: Q2, 2017 By the Numbers : August 7, 2017 Aug 07 2017
NRC Health publishes 10 millionth online patient rating Aug 07 2017
National Research posts 2Q profit Aug 01 2017
National Research Corporation Announces Second Quarter 2017 Results Aug 01 2017
National Research Corporation to Broadcast its 2017 Second Quarter Conference Call Live on the... Jul 18 2017
One Of 2016's Best IPO Stocks May Be Ready To Break Out Again Jul 11 2017
Zacks.com featured highlights: AppFolio, National Research, Telephone and Data Systems and WellCare... Jun 29 2017
Verisk Unit Unveils Property/Casualty Insurance Revenue Drop Jun 27 2017
National Research Corp. :NRCIA-US: Earnings Analysis: Q1, 2017 By the Numbers : May 18, 2017 May 18 2017
Praise during Nursing Home Week: exemplary satisfaction rates from Alabama nursing homes May 15 2017
Investor Network: National Research Corporation to Host Earnings Call May 03 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}